Бронхо-мунал®

General characteristics. Structure:

Active agent: the standardized lyophilisate of lysates of the bacteria most often causing respiratory infections: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis of 7 mg
excipients: (anhydrous) spent on drink gallate; sodium glutamate (anhydrous); Mannitolum (to 77 mg); magnesium stearate; starch prezhelatinizirovanny; indigotin (E132); titanium dioxide (E171); gelatin

Description. Capsules of 7 mg. Light-beige color the powder placed in solid gelatin capsules of the size No. 3, a cover and the case blue opaque.

Pharmacological properties:

Pharmacodynamics. Bronkho-munal and Bronkho-munal P contain the lyophilized lysate of bacteria most of which often cause respiratory infections, including Streptococcus pneumoniae, Haemophilus influenzae, Klebseiella pneumoniae, Klebseiella ozaenae, Staphylococcus aureus, Streptococcus viridans, Streptococcus pyogenes, Moraxella catarrhallis.
Bronkho-munal and Bronkho-munal P stimulate natural protective powers of an organism against respiratory infections, reducing the frequency and duration of such infections which proceed in easier form. Use Bronkho-munala or Bronkho-munal P allows to reduce need for antibiotics.
Bronkho-munal and Bronkho-munal P stimulate both local cellular, and a humoral immune response in a mucous membrane of respiratory tracts, and also a system immune response. Drug increases nonspecific immunity of an organism. In preclinical and clinical trials such effects of Bronkho-munal on protective mechanisms of an organism were shown:
drug stimulates activity of alveolar macrophages who cosecrete the cytokines protecting from infections;
drug increases quantity of CD4 of T lymphocytes;
drug activates peripheral mononukleara;
drug increases concentration of secretory IgA on mucous membranes of respiratory tracts and a digestive tract;
Bronkho-munal and Bronkho-munal P stimulate products of protective adhesive molecules;
Bronkho-munal and Bronkho-munal P reduce concentration of antibodies of IgE in blood that can inhibit mechanisms of development of reactions.

Pharmacokinetics. At oral administration of drug the bacterial lysate collects in peyerovy plaques of a mucous membrane of a digestive tract.
Cells of peyerovy plaques absorb antigen and present it to subepithelial lymphoid cells, inducing thus a humoral immune response that leads to the raised products of IgA in a mucous membrane which inhibit penetration of microorganisms.
Antigen also stimulates by means of interaction with peyerovy plaques lymphoid cells which migrate through regional lymph nodes to the chest canal, then — in a blood stream.
With a blood-groove they migrate in a mucous membrane of a digestive tract, airways, and also mucous membranes of other bodies where they perform protective function, raising a possibility of a host defense against bacteria and viruses.

Indications to use:

As means of adjuvant therapy Bronkho-munal and Bronkho-munal P can be applied at all respiratory infections.
Preventively Bronkho-munal is applied at recurrent respiratory infections and ENT organs (chronic bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis).

Route of administration and doses:

Drug Bronkho-munal is used at adults and children 12 years, Bronkho-munal P — at children from 6 months to 12 years are more senior.
For prevention of respiratory infections: 1 capsule a day within 10 days 3 months in a row (at an opportunity the patient has to begin treatment every month in the same day so that the interval between separate courses made 20 days).
At an acute disease: 1 capsule a day during 10 or 30 days in a row. In each of the next 2 months it is possible to accept on 1 capsule within 10 days in a row. The interval between courses has to make 20 days. Drug can be accepted in parallel with antibiotics.
For small children who cannot swallow the whole capsule of drug Bronkho-munal P it is necessary to pour out capsule contents in capacity with a small amount of liquid (tea, milk or juice) and to allow to drink to the child.
Drug should be accepted on an empty stomach.
If time of administration of drug is passed, it is necessary to accept it next day.

Features of use:

After vaccination it is possible to begin administration of drug with a live vaccine not earlier, than in 4 weeks.

Side effects:

Drug very seldom causes side effects. They are observed approximately at 4,5% of patients: in most cases they were poorly expressed also passing. There were single cases of hypersensitivity reactions to drug. At development of such reactions administration of drug needs to be stopped. Fever and disorders of a digestive tract is possible (pain in epigastriums, nausea, vomiting, diarrhea).

Interaction with other medicines:

Are not described.

Contraindications:

Hypersensitivity to drug components.

Overdose:

It is unknown whether the drug overdose causes heavy side reactions. Cases of intoxication were not observed.
In case of overdose it is necessary to see a doctor.

Storage conditions:

At a temperature of 15-25 °C. To store in the place, unavailable to children. Period of validity of the drug Bronkho-munal® P 5 of years.

Issue conditions:

According to the recipe

Packaging:

Capsules of 7 mg. On 10 капс. in the blister, on 1 or 3 blisters in a pack cardboard.